Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Data for Exploring the potential of multinuclear solid‐state 1H, 13C, and 35Cl magnetic resonance to characterize static and dynamic disorder in pharmaceutical hydrochlorides

Tools
- Tools
+ Tools

Szell, Patrick M.J., Rehman, Zainab, Tatman, Ben P., Hughes, Leslie P., Blade, Helen and Brown, Steven P. (2022) Data for Exploring the potential of multinuclear solid‐state 1H, 13C, and 35Cl magnetic resonance to characterize static and dynamic disorder in pharmaceutical hydrochlorides. [Dataset]

[img] Microsoft Word (Readme file)
WRAP Data description.rtf - Published Version
Available under License Creative Commons Attribution 4.0.

Download (128Kb)
[img] Archive (ZIP) (Dataset)
WRAP Dataset.zip - Published Version
Available under License Creative Commons Attribution 4.0.

Download (6Mb)
Official URL: http://wrap.warwick.ac.uk/169849/

Request Changes to record.

Abstract

Crystallographic disorder, whether static or dynamic, can be detrimental to the physical and chemical stability, ease of crystallization and dissolution rate of an active pharmaceutical ingredient. Disorder can result in a loss of manufacturing control leading to batch to batch variability and can lengthen the process of structural characterization. The range of NMR active nuclei makes solid-state NMR a unique technique for gaining nucleus-specific information about crystallographic disorder. Here, we explore the use of high-field 35Cl solid-state NMR at 23.5 T to characterize both static and dynamic crystallographic disorder: Specifically, dynamic disorder occurring in duloxetine hydrochloride (1), static disorder in promethazine hydrochloride (2), and trifluoperazine dihydrochloride (3). In all structures, the presence of crystallographic disorder was confirmed by 13C cross-polarization magic-angle spinning (CPMAS) NMR and supported by GIPAW-DFT calculations, and in the case of 3, 1H MAS NMR provided additional confirmation. Applying 35Cl solid-state NMR to these compounds, we show that higher magnetic fields are beneficial for resolving the crystallographic disorder in 1 and 3, while broad spectral features were observed in 2 even at higher fields. Combining the data obtained from 1H, 13C, and 35Cl NMR, we show that 3 exhibits a unique case of disorder involving the +N-H hydrogen positions of the piperazinium ring, driving the chloride anions to occupy 3 distinct sites.

Item Type: Dataset
Subjects: Q Science > QC Physics
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Science, Engineering and Medicine > Science > Physics
Library of Congress Subject Headings (LCSH): Crystallography, Nuclear magnetic resonance spectroscopy, Pharmaceutical chemistry, X-ray crystallography, Organic compounds, Density functionals
Publisher: University of Warwick, Department of Physics
Official Date: 5 October 2022
Dates:
DateEvent
5 October 2022Published
5 October 2022Available
5 October 2022Created
Status: Not Peer Reviewed
Publication Status: Published
Media of Output (format): .cif, .magres, .xyz, .ased, .txt
Access rights to Published version: Open Access (Creative Commons)
Copyright Holders: University of Warwick
Description:

Dataset contains following items:
DFT-calculated data
Solid-state NMR Data

Date of first compliant deposit: 5 October 2022
Date of first compliant Open Access: 5 October 2022
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
KTP11570Innovate UK and AstraZenecaUNSPECIFIED
UNSPECIFIED[EPSRC] Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
UNSPECIFIEDPfizer UKhttp://dx.doi.org/10.13039/100009032
UNSPECIFIEDBrukerUNSPECIFIED
UNSPECIFIEDUniversity of Warwickhttp://dx.doi.org/10.13039/501100000741
EP/T015063/1[EPSRC] Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
UNSPECIFIED[BBSRC] Biotechnology and Biological Sciences Research Councilhttp://dx.doi.org/10.13039/501100000268
UNSPECIFIEDAdvantage West Midlandshttp://dx.doi.org/10.13039/100014381
UNSPECIFIED[ERDF] European Regional Development Fundhttp://dx.doi.org/10.13039/501100008530
Related URLs:
  • Related item in WRAP
  • Other
Contributors:
ContributionNameContributor ID
DepositorBrown, Steven P.1193

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us